Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy.
Geert
G
Maleux
Johan
J
Vaninbroukx
Sam
S
Heye
Eric
E
van Cutsem
Raymond
R
Oyen
D000783:Aneurysm / Q000139:chemically induced* / Q000000981:diagnostic imaging; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D018207:Angiomyolipoma / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000473:pathology*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin